On December 27, 2023, Algernon Pharmaceuticals Inc. closed the transaction. The transaction included participation from certain insiders of the company for gross proceeds of CAD 173,505. The company paid cash finder?s fees totaling CAD 9,000 and issued 120,000 finders warrants to eligible finders for investors introduced to the company by the eligible finder.